A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee
- PMID: 23144445
- DOI: 10.1136/annrheumdis-2012-202239
A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee
Abstract
Objective: To determine if inhibition of inducible nitric oxide synthase (iNOS) with cindunistat hydrochloride maleate slows progression of osteoarthritis (OA) METHODS: This 2-year, multinational, double-blind, placebo-controlled trial enrolled patients with symptomatic knee OA (Kellgren and Lawrence Grade (KLG) 2 or 3). Standard OA therapies were permitted throughout. Patients were randomly assigned to cindunistat (50 or 200 mg/day) or placebo. Randomisation was stratified by KLG. Radiographs to assess joint space narrowing (JSN) were acquired using the modified Lyon-schuss protocol at baseline, week 48 and 96.
Results: Of 1457 patients (50 mg/day, n=485; 200 mg/day, n=486; placebo, n=486), 1048 (71.9%) completed the study. Patients were predominantly women; 56% had KLG3. The primary analysis did not demonstrate superiority of cindunistat versus placebo for rate of change in JSN. In KLG2 patients, JSN after 48 weeks was lower with cindunistat 50 mg/day versus placebo (p=0.032). Least-squares mean±SE JSN with cindunistat 50 mg/day ( -0.048±0.028 mm) and 200 mg/day (-0.062±0.028 mm) were 59.9% (95% CI 6.8% to 106.9%) and 48.7% (95% CI -8.4% to 93.9%) of placebo, improvement was not maintained at 96 weeks. No improvement was observed for KLG3 patients at either time-point. Cindunistat did not improve joint pain or function, but was generally well tolerated.
Conclusions: Cindunistat (50 or 200 mg/day) did not slow the rate of JSN versus placebo. After 48-weeks, KLG2 patients showed less JSN; however, the improvement was not sustained at 96-weeks. iNOS inhibition did not slow OA progression in KLG3 patients. CLINICAL TRIAL LISTING: NCT00565812.
Similar articles
-
Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens.Ann Rheum Dis. 2015 May;74(5):851-8. doi: 10.1136/annrheumdis-2013-203954. Epub 2014 Jan 6. Ann Rheum Dis. 2015. PMID: 24395557 Clinical Trial.
-
Considerations when designing a disease-modifying osteoarthritis drug (DMOAD) trial using radiography.Semin Arthritis Rheum. 2013 Aug;43(1):1-8. doi: 10.1016/j.semarthrit.2012.11.006. Epub 2013 Jan 2. Semin Arthritis Rheum. 2013. PMID: 23290692 Clinical Trial.
-
Change in regional cartilage morphology and joint space width in osteoarthritis participants versus healthy controls: a multicentre study using 3.0 Tesla MRI and Lyon-Schuss radiography.Ann Rheum Dis. 2010 Jan;69(1):155-62. doi: 10.1136/ard.2008.099762. Ann Rheum Dis. 2010. PMID: 19103634
-
Progressive increase in body mass index is not associated with a progressive increase in joint space narrowing in obese women with osteoarthritis of the knee.Ann Rheum Dis. 2009 Nov;68(11):1734-8. doi: 10.1136/ard.2007.085530. Epub 2008 Dec 5. Ann Rheum Dis. 2009. PMID: 19060003
-
Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial.Arthritis Rheum. 2005 Jul;52(7):2015-25. doi: 10.1002/art.21122. Arthritis Rheum. 2005. PMID: 15986343 Clinical Trial.
Cited by
-
Inter-Reader Consistency and Exclusionary Findings During Radiographic Screening for Phase 3 Trials of Tanezumab in Patients With Osteoarthritis.Osteoarthr Imaging. 2022 Sep-Dec;2(3-4):100082. doi: 10.1016/j.ostima.2022.100082. Epub 2022 Nov 15. Osteoarthr Imaging. 2022. PMID: 38343426 Free PMC article.
-
Lymphatic vessels: roles and potential therapeutic intervention in rheumatoid arthritis and osteoarthritis.Theranostics. 2024 Jan 1;14(1):265-282. doi: 10.7150/thno.90940. eCollection 2024. Theranostics. 2024. PMID: 38164153 Free PMC article. Review.
-
Regulatory role of NFAT1 signaling in articular chondrocyte activities and osteoarthritis pathogenesis.Biocell. 2023;47(10):2125-2132. doi: 10.32604/biocell.2023.030161. Epub 2023 Nov 8. Biocell. 2023. PMID: 37974562
-
Placebo effects in osteoarthritis: implications for treatment and drug development.Nat Rev Rheumatol. 2023 Oct;19(10):613-626. doi: 10.1038/s41584-023-01021-4. Epub 2023 Sep 11. Nat Rev Rheumatol. 2023. PMID: 37697077 Free PMC article. Review.
-
Comparative validation of the knee inflammation MRI scoring system and the MRI osteoarthritis knee score for semi-quantitative assessment of bone marrow lesions and synovitis-effusion in osteoarthritis: an international multi-reader exercise.Ther Adv Musculoskelet Dis. 2023 Jul 12;15:1759720X231171766. doi: 10.1177/1759720X231171766. eCollection 2023. Ther Adv Musculoskelet Dis. 2023. PMID: 37457557 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources